RedHill Biopharma shares are trading lower after the company announced it received a letter from the Nasdaq regarding minimum bid price deficiency.
Portfolio Pulse from Benzinga Newsdesk
RedHill Biopharma's shares are trading lower after the company received a letter from the Nasdaq regarding minimum bid price deficiency.
September 25, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RedHill Biopharma's stock price is expected to be negatively impacted in the short term due to the Nasdaq's notice on minimum bid price deficiency.
RedHill Biopharma received a notice from Nasdaq regarding minimum bid price deficiency. This news has already led to a decrease in the company's stock price and is likely to continue to negatively impact it in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100